CE-178,253

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H23Cl2N7O
Molecular Weight	496.392
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCNC1(CN(C1)C2=NC(C)=NC3=C(C(=NN23)C4=CC=CC=C4Cl)C5=CC=C(Cl)C=C5)C(N)=O

InChI

InChIKey=XJFUIILGVMOOHV-UHFFFAOYSA-N

InChI=1S/C24H23Cl2N7O/c1-3-28-24(22(27)34)12-32(13-24)23-30-14(2)29-21-19(15-8-10-16(25)11-9-15)20(31-33(21)23)17-6-4-5-7-18(17)26/h4-11,28H,3,12-13H2,1-2H3,(H2,27,34)

HIDE SMILES / InChI

Molecular Formula	C24H23Cl2N7O
Molecular Weight	496.392
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20712891
Curator's Comment: Description was created based on several sources, including http://www.sciencedirect.com/science/article/pii/S0040402008018735

CE-178,253 benzenesulfonate is a CB1 antagonist discovered by Pfizer medicinal chemists. In vitro, CE-178,253 exhibits sub-nanomolar potency at human CB1 receptors in both binding (Ki = 0.33 nM) and functional assays (Ki = 0.07 nM). CE-178,253 has low affinity (Ki > 10,000 nM) for human CB2 receptors. In vivo, CE-178,253 exhibits concentration-dependent anorectic activity in both fast-induced re-feeding and spontaneous nocturnal feeding FI models. In two preclinical models of obesity, CE-178,253 dose-dependently promotes weight loss in diet-induced obese rats and mice.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20712891	Antagonist 2778		0.33 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20712891	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.	2007 Oct	17630359
The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task.	2008 Aug 20	18602386

Patents

Sample Use Guides

In Vivo Use Guide

Rats: CE-178,253 dose-dependently inhibited spontaneous nocturnal FI (0.3 mg/kg, 1 mg/kg and 3 mg/kg, p.o.)

Route of Administration: Oral

In Vitro Use Guide

CE-178,253 was tested at 1 uM concentration for binding affinity at different receptors, ion channels, and uptake sites

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:25:48 GMT 2023` Edited by `admin` on `Fri Dec 15 15:25:48 GMT 2023`
Record UNII	FW6JCF60XU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CE-178,253

Common Name

English

CE 178253

Code

English

CE-178253

Code

English

3-AZETIDINECARBOXAMIDE, 1-(7-(2-CHLOROPHENYL)-8-(4-CHLOROPHENYL)-2-METHYLPYRAZOLO(1,5-A)-1,3,5-TRIAZIN-4-YL)-3-(ETHYLAMINO)-

Systematic Name

English

Code System Code Type Description

CAS

736993-54-7